---
title: "Financial Guidance for FY 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278598086.md"
description: "Biofrontera AG has announced its financial guidance for FY 2026, projecting sales revenue between EUR 14 million and EUR 16 million, with adjusted EBITDA expected to range from EUR +3.5 million to EUR +5.1 million. The guidance excludes earn-out from Biofrontera Inc. related to U.S. sales of Ameluz, anticipated to be between EUR 3.5 million and EUR 4.5 million. The company notes that U.S. operations will be classified as discontinued under IFRS accounting standards, affecting reported sales revenue and EBITDA."
datetime: "2026-03-10T17:55:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278598086.md)
  - [en](https://longbridge.com/en/news/278598086.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278598086.md)
---

# Financial Guidance for FY 2026

**Biofrontera AG**

by Investor Relations

Public disclosure of inside information according to article 17 MAR

_Keywords: Forecast / Full Year_

**Biofrontera AG: Financial Guidance for FY 2026**

Leverkusen (pta000/10.03.2026/18:55 UTC+1)

The Management Board today provides the following financial **guidance for fiscal year 2026:**

-   **Sales revenue:** EUR 14 million –EUR 16 million
-   **Adjusted EBITDA:** EUR +3.5 million – EUR +5.1 million (unadjusted: EUR -0.5 million- EUR +0.5 million)

In 2026 Biofrontera expects sales revenues between EUR 14 and 16 million, (2025 adjusted sales revenues EUR 19 million, unadjusted sales revenues EUR 13 million). Adjusted and unadjusted sales revenues don't include the earn out from Biofrontera Inc, as earn out is a consideration from the business unit sale, not operational sales revenues. The earn out is based on the US-sales of Ameluz and is expected between EUR 3.5 million and 4.5 million in 2026 (2025: EUR 1.8 million).

Adjusted EBITDA for 2026 is expected to be between EUR 3.5 million and EUR 5.1 million (2025 adjusted EBITDA: EUR 4 million to 5 million, unadjusted EBITDA EUR -1.3 million to -0.8 million).

The company provides adjusted and unadjusted figures to allow an easier comparison of the business operations due to the following reasons: Following the sale of the U.S. business to Biofrontera Inc., IFRS accounting standards require the Company to classify the U.S. operations as discontinued operations. Accordingly, revenues, expenses, taxes and any cash inflows related to the disposed U.S. business, including potential earn-out payments, will not be included in reported sales revenue or EBITDA.

Instead, all results associated with the discontinued U.S. operations will be presented in the income statement as a single line item under "net result from discontinued operations", impacting net profit or loss.

(end)

Emitter:

Biofrontera AGHemmelrather Weg 20151377 LeverkusenGermany

Contact Person:

Investor Relations

Phone:

+49 (0) 214 87 63 20

E-Mail:

ir@biofrontera.com

Website:

www.biofrontera.com

ISIN(s):

DE000A4BGGM7 (Share)

Stock Exchange(s):

Regulated Market in Dusseldorf, Frankfurt; Free Market in Munich, Stuttgart, Tradegate BSX

\[ source: https://www.pressetext.com/news/1773165300863 \]

(c) pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext. Archive: https://www.pressetext.com/channel/Adhoc The emitter is responsible for the content. Contact: adhoc@pressetext.com or +43-1-81140-0.

### Related Stocks

- [BFRI.US](https://longbridge.com/en/quote/BFRI.US.md)
- [BFRIW.US](https://longbridge.com/en/quote/BFRIW.US.md)

## Related News & Research

- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Buffett’s 90/10 index fund strategy gains fresh relevance](https://longbridge.com/en/news/286651662.md)
- [Lifeway Foods 10% Owner Sold Shares Worth Over $67M](https://longbridge.com/en/news/287117286.md)
- [Watch live: The Hill's Decision Desk 2026 – Data Nerds](https://longbridge.com/en/news/286910191.md)
- [Neuronetics 10% owner Jorey Chernett buys 100,000 shares for $117,000](https://longbridge.com/en/news/287097316.md)